Cargando…

The prevalence and prognostic value of KRAS co‐mutation subtypes in Chinese advanced non‐small cell lung cancer patients

OBJECTIVE: KRAS mutation plays a critical role in the initiation and development of non‐small cell lung cancer (NSCLC). KRAS‐mutant patients exhibit diverse response to chemotherapy. KRAS co‐mutation subtypes and their prognosis value in advanced Chinese NSCLC patients remain largely elusive. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cai, Dongjing, Hu, Chengping, Li, Li, Deng, Shichao, Yang, Jing, Han‐Zhang, Han, Li, Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943152/ https://www.ncbi.nlm.nih.gov/pubmed/31709742 http://dx.doi.org/10.1002/cam4.2682

Ejemplares similares

The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations
por: Zheng, Difan, et al.
Publicado: (2016)

Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer
por: Judd, Julia, et al.
Publicado: (2021)

Prognostic value of neuron-specific enolase in patients with advanced and metastatic non-neuroendocrine non-small cell lung cancer
por: Yan, Peng, et al.
Publicado: (2021)

Revealing the clinical significance and prognostic value of small nucleolar RNA SNORD31 in hepatocellular carcinoma
por: Ding, Yuan, et al.
Publicado: (2020)

Prognostic value of KRAS subtype in patients with PDAC undergoing radical resection
por: Dai, Manxiong, et al.
Publicado: (2022)

Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer
por: Sun, Jong-Mu, et al.
Publicado: (2013)

KRAS mutation in lung metastases from colorectal cancer: prognostic implications
por: Ghidini, Michele, et al.
Publicado: (2015)

Clinicopathologic features and prognostic value of KRAS, NRAS and BRAF mutations and DNA mismatch repair status: A single‐center retrospective study of 1,834 Chinese patients with Stage I–IV colorectal cancer
por: Guo, Tian‐An, et al.
Publicado: (2019)

Meta-analysis of diagnostic and prognostic value of miR-126 in non-small cell lung cancer
por: Sun, Lin, et al.
Publicado: (2020)

Prognostic Value of KRAS Mutations in Colorectal Cancer Patients
por: Koulouridi, Asimina, et al.
Publicado: (2022)

Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review
por: Strickler, John H, et al.
Publicado: (2023)

Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer
por: Fakih, Marwan, et al.
Publicado: (2022)

Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients
por: Liu, Si-Yang, et al.
Publicado: (2020)

Correlation between KRAS mutation subtypes and prognosis in Chinese advanced non‐squamous non‐small cell lung cancer patients
por: Liu, Feiwen, et al.
Publicado: (2023)

KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma
por: Bournet, Barbara, et al.
Publicado: (2016)

Prognostic value of Ki-67 in nasopharyngeal carcinoma: a meta-analysis
por: Li, Yulin, et al.
Publicado: (2021)

Prognostic value of KRAS/TP53/PIK3CA in non-small cell lung cancer
por: Zhao, Jiayi, et al.
Publicado: (2019)

Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review
por: Kim, Jung Han, et al.
Publicado: (2017)

The diagnostic accuracy of circulating free DNA for the detection of KRAS mutation status in colorectal cancer: A meta‐analysis
por: Xie, Wenli, et al.
Publicado: (2019)

Identification of PPT1 as a lysosomal core gene with prognostic value in hepatocellular carcinoma
por: Tian, Wei, et al.
Publicado: (2023)

Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF
por: Zhuang, Xibin, et al.
Publicado: (2019)

The landscape and prognostic value of immune characteristics in uterine corpus endometrial cancer
por: Liu, Wenli, et al.
Publicado: (2021)

Pancreatic cyst fluid harboring a KRAS mutation
por: Al-Turkmani, M. Rabie, et al.
Publicado: (2019)

Combinatorial approaches for mitigating resistance to KRAS-targeted therapies
por: Warren, Hannah R., et al.
Publicado: (2022)

Validation of the functions and prognostic values of synapse-associated proteins in lower-grade glioma
por: Lin, Han, et al.
Publicado: (2021)

Clinicopathological and prognostic value of S100A4 expression in non-small cell lung cancer: a meta-analysis
por: Zhang, Jing, et al.
Publicado: (2020)

Practical Guidance for the Management of Adverse Events in Patients with KRAS(G12C)-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib
por: Zhang, Jun, et al.
Publicado: (2023)

Poor prognosis of pulmonary sarcomatoid carcinoma with KRAS mutation and ALK fusion
por: Chen, Fangmin, et al.
Publicado: (2019)

KRAS G12V Mutation is an Adverse Prognostic Factor of Chinese Gastric Cancer Patients
por: Fu, Xin-Hui, et al.
Publicado: (2019)

The prognostic value of lncRNA SNHG4 and its potential mechanism in liver cancer
por: Jiao, Yan, et al.
Publicado: (2020)

Prognostic and predictive value of KRAS mutation number in metastatic colorectal cancer
por: Ucar, Gokhan, et al.
Publicado: (2020)

Prognostic Value of Autophagy, Microsatellite Instability, and KRAS Mutations in Colorectal Cancer
por: Wang, Yuanyuan, et al.
Publicado: (2021)

Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis
por: Li, Xiao-Song, et al.
Publicado: (2020)

Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients
por: Cheng, He, et al.
Publicado: (2020)

Prognostic Value of KRAS Exon 3 and Exon 4 Mutations in Colorectal Cancer Patients
por: Guo, Tianan, et al.
Publicado: (2021)

The Prevalence and Concurrent Pathogenic Mutations of KRAS(G12C) in Northeast Chinese Non-small-cell Lung Cancer Patients
por: Liu, Yan, et al.
Publicado: (2021)

Prognostic value of serum CYFRA21-1 and CEA for non-small-cell lung cancer
por: Zhang, Zhi-Hui, et al.
Publicado: (2015)

The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer
por: Fernández Montes, Ana, et al.
Publicado: (2023)

Immunohistochemistry‐Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer
por: Li, Yaqi, et al.
Publicado: (2020)

The value of haematological parameters and serum tumour markers for predicting KRAS mutations in 784 Chinese colorectal cancer patients: a retrospective analysis
por: Cao, Yinghao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2ra2ci73a18l4oknaf28pdcbah